http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 16 Dec 2024 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Press+Releases/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html <ul class="bwlistdisc"> <li> <b>Former CEO, Sander van Deventer to become President of R&amp;D</b> </li> <li> <b>Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package</b> </li> <li> <b>Expansion of corporate footprint into the US (Boston)</b> </li> </ul> <p> AMSTERDAM &amp; BOSTON--(BUSINESS WIRE)-- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20241216441837/en/" rel="nofollow">https://www.businesswire.com/news/home/20241216441837/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20241216441837/en/2332881/4/IMG_1593.jpg" alt="VectorY strengthens Leadership Team with appointment of Jim Scibetta http://www.streetinsider.com/Business+Wire/VectorY+Strengthens+Leadership+Team+with+Appointment+of+Jim+Scibetta+as+New+CEO/24107247.html Mon, 16 Dec 2024 07:00:00 -0400 A.02975482 A.10141387 A.33640718 BIVN O.00168667 O.00358218 O.01521891 PCRX